| WHITEHAWK THERAPEUTICS |
| USA |
| Gesundheit |
| US00032Q1040 / A3CSR9 |
| 3350 (Frankfurt) / WHWK (NASDAQ) |
| FRA:3350, ETR:3350, 3350:GR, NASDAQ:WHWK |
| - |
| https://ir.whitehawktx.co.. |
|
Whitehawk Therapeutics, Inc. is an oncology biotechnology company focused on the discovery and development of antibody-drug conjugate (ADC) therapies for cancer. The company’s primary objective is to leverage next-generation ADC platform technologi..
>Volltext.. |
| 208.21 Mio. EUR |
| 101.69 Mio. EUR |
| - |
| -104.77 Mio. EUR |
| -98.9 Mio. EUR |
| -1.43 EUR |
| - |
| 29.71 Mio. EUR |
| - |
| 11.13 |
| -100% |
| -492.69% |
| - |
| - |
| - |
| WHITEHAWK THERAPEUTICS, WHITEHAWK THERAPEUTIC, AADI BIOSCIENCES |
| 15.05.26 |
|